Moderate

Gestational diabetes mellitus (GDM) — screening, targets & treatment

Glucose intolerance first recognised in pregnancy; raises macrosomia, shoulder dystocia, pre-eclampsia, neonatal hypoglycaemia and stillbirth risk. DRAFT for clinician review. · Obstetric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

GDM is hyperglycaemia detected in pregnancy that is not overt diabetes. Diagnosed by 75 g OGTT at 24-28 weeks (earlier if high risk: prior GDM, BMI >= 30, previous macrosomic baby >= 4.5 kg, first-degree relative with diabetes, high-risk ethnicity incl. South Asian). NICE NG3 diagnostic thresholds: fasting >= 5.6 mmol/L or 2-hour >= 7.8 mmol/L (a single abnormal value diagnoses). Management is tiered: diet/exercise first, then metformin, then insulin. Good glycaemic control reduces fetal and maternal complications. [verify local — WHO/IADPSG thresholds differ; India often uses DIPSI single-step 2-h >= 7.8 mmol/L].

Red flags

  • Fasting glucose >= 7.0 at diagnosis or very high HbA1c (likely overt diabetes — fetal anomaly risk, needs urgent control)
  • Reduced fetal movements / abnormal CTG
  • Rapidly accelerating fetal growth or polyhydramnios (macrosomia -> shoulder dystocia risk)
  • Features of pre-eclampsia (BP, proteinuria, symptoms)
  • Recurrent hypoglycaemia on treatment
  • Ketonuria / symptoms suggesting DKA (rare in GDM, consider overt T1DM)

Assessment

Differential diagnosis

  • Pre-existing (overt) type 1 or type 2 diabetes first detected in pregnancy (HbA1c >= 48, random glucose >= 11.1)
  • Impaired glucose tolerance
  • Stress/steroid-induced hyperglycaemia (e.g. after antenatal corticosteroids)
  • MODY (young, strong family history, mild fasting hyperglycaemia)

Investigations

  • 75 g OGTT at 24-28 weeks (or booking/early if risk factors, repeat 24-28 wk if normal)
  • Diagnostic (NICE NG3): fasting >= 5.6 mmol/L OR 2-h >= 7.8 mmol/L
  • HbA1c at booking to exclude pre-existing diabetes (>= 48 mmol/mol = overt)
  • Capillary self-monitoring: fasting + 1 h post-meal (or pre-meal) daily once diagnosed
  • Growth/liquor ultrasound (serial, for macrosomia/polyhydramnios); fetal surveillance third trimester
  • Baseline U&E, consider retinal/renal review if overt diabetes
  • Urine for ketones/protein if symptomatic

Management

  • Confirm diagnosis on OGTT; distinguish GDM from previously undiagnosed overt diabetes (HbA1c/random glucose)
  • Refer to joint diabetes-antenatal clinic within ~1 week; dietitian review
  • Start lifestyle: low-glycaemic-index diet, portion control, 30 min daily activity; home glucose monitoring
  • Set glycaemic targets: fasting < 5.3; 1-h post-meal < 7.8 (or 2-h post-meal < 6.4) mmol/L; keep > 4 to avoid hypoglycaemia
  • If targets not met within 1-2 weeks of lifestyle -> add metformin; add/switch to insulin if still not met or metformin not tolerated/contraindicated
  • Immediate insulin (+/- metformin) if fasting glucose >= 7.0 mmol/L at diagnosis, or 6.0-6.9 with macrosomia/polyhydramnios
  • Serial growth scans; plan timing/mode of birth (offer birth by 40+6; earlier if complications/macrosomia)
  • Intrapartum: monitor maternal glucose hourly, keep 4-7 mmol/L, variable-rate insulin if needed; anticipate shoulder dystocia and neonatal hypoglycaemia
  • Postnatal: stop GDM medication after delivery; check fasting glucose/HbA1c at ~6-13 weeks; lifelong annual diabetes screening + lifestyle advice (high future T2DM risk)

Drugs & doses

Metformin 500 mg PO once daily with evening meal, titrate up to 1 g twice daily (max ~2-2.5 g/day); first-line oral agent, pregnancy-acceptable; may cause GI upset [verify local]
Insulin (isophane/NPH and/or rapid-acting e.g. aspart) titrated to glucose profile — preferred if rapid control needed or FPG >= 7.0; no fixed dose, individualised [verify local dose]
Glibenclamide 2.5-5 mg PO (up to 20 mg/day) — only if metformin declined/not tolerated and insulin declined [verify local]
Antenatal corticosteroids if preterm birth anticipated: betamethasone 12 mg IM x2 — WARN causes transient hyperglycaemia, intensify monitoring/insulin for 24-48 h
Folic acid 5 mg PO daily preconception-12 weeks (higher-dose, as for pre-existing diabetes) [verify local]
Aspirin 150 mg PO nocte from 12 weeks (pre-eclampsia prophylaxis if additional risk factors)

Disposition

Outpatient joint diabetes-antenatal clinic management for most. Admit for poor control, pre-eclampsia, reduced fetal movements, or planned induction. Deliver in unit with neonatal facilities (hypoglycaemia/shoulder dystocia risk). Arrange postnatal glucose check 6-13 weeks and annual screening; lifestyle and contraception counselling.

Complications & pitfalls

  • Maternal: pre-eclampsia, polyhydramnios, operative/instrumental delivery, future type 2 diabetes
  • Fetal/neonatal: macrosomia, shoulder dystocia, birth trauma, neonatal hypoglycaemia, jaundice, respiratory distress
  • Stillbirth (poor control)
  • Long-term offspring obesity/metabolic risk

Exam pearls

  • A single abnormal OGTT value (fasting >= 5.6 or 2-h >= 7.8) diagnoses GDM under NICE.
  • Fasting glucose >= 7.0 at diagnosis = go straight to insulin and suspect overt diabetes.
  • Antenatal steroids cause a 24-48 h hyperglycaemic spike — pre-empt with extra monitoring/insulin.
  • Stop all glucose-lowering drugs immediately after delivery; neonate needs early feeding + glucose checks.
  • GDM confers high lifelong T2DM risk — arrange postnatal OGTT/HbA1c and annual screening.
  • In India, DIPSI 2-h 75 g >= 7.8 mmol/L (non-fasting) is widely used — confirm local pathway.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.